A Louisiana jury found that Johnson & Johnson, the makers of Risperdal made false and misleading claims to doctors about the safety and efficacy of Risperdol, an antipsychotic drug. The jury awarded $257.7 million in damages to the State of Louisiana for violations of Medical Assistance Programs Integrity Law. The State claimed in the lawsuit that Johnson & Johnson had misrepresented to doctors within the state that Risperdal was more effective than other antipsychotic drugs and did not fully disclose the drug's link to diabetes. The F.D.A. has previously sent a warning letter about the misleading statements. Last year a West Virginia judge also found against Johnson & Johnson and entered a judgment against it for $3.95 million.